60 degrees pharmaceuticals signs clinical trial agreements with all planned trial sites for tafenoquine babesiosis study

60 degrees pharma begins enrolling patients for a tafenoquine babesiosis trial at yale, tufts, and rhode island hospital, with results expected sept., 2025

SXTP Ratings Summary

SXTP Quant Ranking